ATE356995T1 - Verfahren zur identifizierung von mitteln zur behandlung von diabetes - Google Patents

Verfahren zur identifizierung von mitteln zur behandlung von diabetes

Info

Publication number
ATE356995T1
ATE356995T1 AT02739056T AT02739056T ATE356995T1 AT E356995 T1 ATE356995 T1 AT E356995T1 AT 02739056 T AT02739056 T AT 02739056T AT 02739056 T AT02739056 T AT 02739056T AT E356995 T1 ATE356995 T1 AT E356995T1
Authority
AT
Austria
Prior art keywords
treating diabetes
identifying agents
mnk2b
mnk2a
methods
Prior art date
Application number
AT02739056T
Other languages
English (en)
Inventor
Christina Bendz
Staffan Lake
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20284509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE356995(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Application granted granted Critical
Publication of ATE356995T1 publication Critical patent/ATE356995T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT02739056T 2001-06-18 2002-06-18 Verfahren zur identifizierung von mitteln zur behandlung von diabetes ATE356995T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0102147A SE0102147D0 (sv) 2001-06-18 2001-06-18 New methods

Publications (1)

Publication Number Publication Date
ATE356995T1 true ATE356995T1 (de) 2007-04-15

Family

ID=20284509

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02739056T ATE356995T1 (de) 2001-06-18 2002-06-18 Verfahren zur identifizierung von mitteln zur behandlung von diabetes

Country Status (13)

Country Link
US (1) US20030022241A1 (de)
EP (1) EP1397681B1 (de)
JP (1) JP4475945B2 (de)
AT (1) ATE356995T1 (de)
AU (1) AU2002311737B2 (de)
CA (1) CA2446284A1 (de)
CY (1) CY1107640T1 (de)
DE (1) DE60218843T2 (de)
DK (1) DK1397681T3 (de)
ES (1) ES2284879T3 (de)
PT (1) PT1397681E (de)
SE (1) SE0102147D0 (de)
WO (1) WO2002103361A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002055664A2 (en) * 2001-01-12 2002-07-18 Exelixis, Inc. Modulating insulin receptor signaling
EP2277552A1 (de) 2001-10-29 2011-01-26 Boehringer Ingelheim International GmbH Mnk kinase proteine und diabetes
US20050202407A1 (en) * 2003-12-01 2005-09-15 Baylor College Of Medicine Methods and assays for screening anti-neoplastic therapeutic agents
EP1817583A4 (de) 2004-12-02 2009-06-03 Univ Massachusetts Gene in zusammenhang mit glukosetransport, polypeptide und verfahren zu ihrer verwendung
EP1991547A2 (de) 2006-03-09 2008-11-19 Pharmacopeia, Inc. 8-heteroarylpurin-mnk2-hemmer zur behandlung von stoffwechselerkrankungen
EP1889847A1 (de) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidine zur pharmazeutischen Anwendung
AR080328A1 (es) 2010-02-26 2012-03-28 Boehringer Ingelheim Int Tienopirimidinas que contienen un grupo alquilo sustituido inhibidoras de quinasas mnk1 y/o mnk2, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de trastornos metabolicos tales como diabetes y obesidad, y trastornos hiperproliferativos, entre otros
AU2011219758A1 (en) 2010-02-26 2012-08-16 Boehringer Ingelheim International Gmbh 4 - [cycloalkyloxy (hetero) arylamino] thieno [2, 3 - d] pyrimidines having Mnkl/ Mnk2 inhibiting activity for pharmaceutical compositions
US20130065914A1 (en) 2010-02-26 2013-03-14 Boehringer Ingelheim International Gmbh Halogen or cyano substituted thieno [2,3-d]pyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
UY33241A (es) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
EP2917185B1 (de) 2012-11-09 2017-05-10 Evotec International GmbH Sulfoximinsubstituierte chinazoline für pharmazeutische zusammensetzungen
ES2693520T3 (es) 2013-12-04 2018-12-12 Evotec International Gmbh Quinazolinas sustituidas con sulfoximina para composiciones farmacéuticas
WO2015091156A1 (en) 2013-12-17 2015-06-25 Boehringer Ingelheim International Gmbh Sulfoximine substituted pyrrolotriazines for pharmaceutical compositions
ES2749186T3 (es) 2014-05-07 2020-03-19 Evotec Int Gmbh Quinazolinas sustituidas con sulfoximina para composiciones farmacéuticas
WO2017068064A1 (en) 2015-10-22 2017-04-27 Selvita S.A. Pyridone derivatives and their use as kinase inhibitors
AU2017239932A1 (en) * 2016-03-31 2018-10-25 Ocean University Of China Method of inhibiting high fat diet-related conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874231A (en) * 1994-08-22 1999-02-23 Mcgill University Methods of screening for non-hormone compounds which effect modulation of polypeptide translation
US6057117A (en) * 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3

Also Published As

Publication number Publication date
SE0102147D0 (sv) 2001-06-18
JP2005500033A (ja) 2005-01-06
WO2002103361A1 (en) 2002-12-27
DE60218843T2 (de) 2007-07-12
PT1397681E (pt) 2007-06-19
EP1397681B1 (de) 2007-03-14
ES2284879T3 (es) 2007-11-16
AU2002311737B2 (en) 2007-06-21
DK1397681T3 (da) 2007-07-16
EP1397681A1 (de) 2004-03-17
DE60218843D1 (de) 2007-04-26
JP4475945B2 (ja) 2010-06-09
CA2446284A1 (en) 2002-12-27
CY1107640T1 (el) 2013-04-18
US20030022241A1 (en) 2003-01-30

Similar Documents

Publication Publication Date Title
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE60031396D1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
DE60236413D1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
DE60309203D1 (de) Iontophoretische verabreichung von rotigotin zur behandlung der parkinson'schen krankheit
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
ATE359079T1 (de) Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
BRPI0313792B8 (pt) utilização de proteína de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
DE602004021847D1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
ATE382347T1 (de) Pharmazeutische zusammensetzung zur verwendung bei der behandlung von malignen erkrankungen, umfassend eine kombination aus bisphosphonaten, einem cox-2 inhibitor und einem taxol
DE602004016547D1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
DE69930419D1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch
DE50210279D1 (de) Screeningverfahren mit bnpi und dnpi
DE60225845D1 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von diabetes, insulinresistenz und dyslipidämie
DE602004015321D1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
DE69928814D1 (de) Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten
ATE288263T1 (de) Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)
ATE337783T1 (de) Neue therapeutische verwendung eines derivates von thienylcyclohexylamine zur behandlung von schmerzen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1397681

Country of ref document: EP

RZN Patent revoked